Zobrazeno 1 - 10
of 875
pro vyhledávání: '"G. Bivona"'
Autor:
David Gonzalez-Martinez, Lee Roth, Thomas R. Mumford, Juan Guan, Anh Le, Robert C. Doebele, Bo Huang, Asmin Tulpule, Magdalena Niewiadomska-Bugaj, Trever G. Bivona, Lukasz J. Bugaj
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-17 (2024)
Abstract Drug resistance remains a challenge for targeted therapy of cancers driven by EML4-ALK and related fusion oncogenes. EML4-ALK forms cytoplasmic protein condensates, which result from networks of interactions between oncogene and adapter prot
Externí odkaz:
https://doaj.org/article/369d4a9ed829495a9689692c1e1918f3
Autor:
Sebastijan Hobor, Maise Al Bakir, Crispin T. Hiley, Marcin Skrzypski, Alexander M. Frankell, Bjorn Bakker, Thomas B. K. Watkins, Aleksandra Markovets, Jonathan R. Dry, Andrew P. Brown, Jasper van der Aart, Hilda van den Bos, Diana Spierings, Dahmane Oukrif, Marco Novelli, Turja Chakrabarti, Adam H. Rabinowitz, Laila Ait Hassou, Saskia Litière, D. Lucas Kerr, Lisa Tan, Gavin Kelly, David A. Moore, Matthew J. Renshaw, Subramanian Venkatesan, William Hill, Ariana Huebner, Carlos Martínez-Ruiz, James R. M. Black, Wei Wu, Mihaela Angelova, Nicholas McGranahan, Julian Downward, Juliann Chmielecki, Carl Barrett, Kevin Litchfield, Su Kit Chew, Collin M. Blakely, Elza C. de Bruin, Floris Foijer, Karen H. Vousden, Trever G. Bivona, TRACERx consortium, Robert E. Hynds, Nnennaya Kanu, Simone Zaccaria, Eva Grönroos, Charles Swanton
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-21 (2024)
Abstract The phenomenon of mixed/heterogenous treatment responses to cancer therapies within an individual patient presents a challenging clinical scenario. Furthermore, the molecular basis of mixed intra-patient tumor responses remains unclear. Here
Externí odkaz:
https://doaj.org/article/a58c4b29e1d8491b8078212067633916
Autor:
Tej D. Azad, Shigeki Nanjo, Michael C. Jin, Jacob J. Chabon, David M. Kurtz, Aadel A. Chaudhuri, Ian D. Connolly, Angela Bik-Yu Hui, Chih Long Liu, David Merriott, Ryan Ko, Christopher Yoo, Justin Carter, Emily Chen, Rene Bonilla, Akito Hata, Nobuyuki Katakami, Kei Irie, Seiji Yano, Ross Okimoto, Trever G. Bivona, Aaron M. Newman, Michael Iv, Seema Nagpal, Melanie Hayden Gephart, Ash A. Alizadeh, Maximilian Diehn
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-10 (2024)
Abstract Cerebrospinal fluid tumor-derived DNA (CSF-tDNA) analysis is a promising approach for monitoring the neoplastic processes of the central nervous system. We applied a lung cancer-specific sequencing panel (CAPP-Seq) to 81 CSF, blood, and tiss
Externí odkaz:
https://doaj.org/article/eaae1e7a290d44c69e031450a6628a56
Autor:
Franziska Haderk, Yu-Ting Chou, Lauren Cech, Celia Fernández-Méndez, Johnny Yu, Victor Olivas, Ismail M. Meraz, Dora Barbosa Rabago, D. Lucas Kerr, Carlos Gomez, David V. Allegakoen, Juan Guan, Khyati N. Shah, Kari A. Herrington, Oghenekevwe M. Gbenedio, Shigeki Nanjo, Mourad Majidi, Whitney Tamaki, Yashar K. Pourmoghadam, Julia K. Rotow, Caroline E. McCoach, Jonathan W. Riess, J. Silvio Gutkind, Tracy T. Tang, Leonard Post, Bo Huang, Pilar Santisteban, Hani Goodarzi, Sourav Bandyopadhyay, Calvin J. Kuo, Jeroen P. Roose, Wei Wu, Collin M. Blakely, Jack A. Roth, Trever G. Bivona
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-19 (2024)
Abstract Targeted therapy is effective in many tumor types including lung cancer, the leading cause of cancer mortality. Paradigm defining examples are targeted therapies directed against non-small cell lung cancer (NSCLC) subtypes with oncogenic alt
Externí odkaz:
https://doaj.org/article/be0a7eca3725431ab19bfe58739629b9
Autor:
Li B
Publikováno v:
Journal of thoracic disease [J Thorac Dis] 2018 Oct; Vol. 10 (10), pp. E748-E749.
Autor:
Brad Li
Drug resistance describes the status when the effectiveness of a medication such as an antimicrobial or an antineoplastic in curing a disease or medical condition is reduced (1). While it is posing threats to clinical care, it is concurrently driving
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08a6f4cc801a877d791d28790b8846ab
https://europepmc.org/articles/PMC6236161/
https://europepmc.org/articles/PMC6236161/
Autor:
Ismail M. Meraz, Mourad Majidi, Bingliang Fang, Feng Meng, Lihui Gao, RuPing Shao, Renduo Song, Feng Li, Yonathan Lissanu, Huiqin Chen, Min Jin Ha, Qi Wang, Jing Wang, Elizabeth Shpall, Sung Yun Jung, Franziska Haderk, Philippe Gui, Jonathan Wesley Riess, Victor Olivas, Trever G. Bivona, Jack A. Roth
Publikováno v:
Communications Biology, Vol 6, Iss 1, Pp 1-17 (2023)
Abstract Osimertinib sensitive and resistant NSCLC NCI-H1975 clones are used to model osimertinib acquired resistance in humanized and non-humanized mice and delineate potential resistance mechanisms. No new EGFR mutations or loss of the EGFR T790M m
Externí odkaz:
https://doaj.org/article/14668810c2ce4d07aa43ff0a81c3c865
Digital multiplexed analysis of circular RNAs in FFPE and fresh non‐small cell lung cancer specimens
Autor:
Carlos Pedraz‐Valdunciel, Stavros Giannoukakos, Nicolas Potie, Ana Giménez‐Capitán, Chung‐Ying Huang, Michael Hackenberg, Alberto Fernandez‐Hilario, Jill Bracht, Martyna Filipska, Erika Aldeguer, Sonia Rodríguez, Trever G. Bivona, Sarah Warren, Cristina Aguado, Masaoki Ito, Andrés Aguilar‐Hernández, Miguel Angel Molina‐Vila, Rafael Rosell
Publikováno v:
Molecular Oncology, Vol 16, Iss 12, Pp 2367-2383 (2022)
Although many studies highlight the implication of circular RNAs (circRNAs) in carcinogenesis and tumor progression, their potential as cancer biomarkers has not yet been fully explored in the clinic due to the limitations of current quantification m
Externí odkaz:
https://doaj.org/article/80cef2ed33524c79919697a56c94f2dd
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jacqueline Morales, David V. Allegakoen, José A. Garcia, Kristen Kwong, Pushpendra K. Sahu, Drew A. Fajardo, Yue Pan, Max A. Horlbeck, Jonathan S. Weissman, W. Clay Gustafson, Trever G. Bivona, Amit J. Sabnis
Publikováno v:
JCI Insight, Vol 7, Iss 23 (2022)
Oncogenic FOXO1 gene fusions drive a subset of rhabdomyosarcoma (RMS) with poor survival; to date, these cancer drivers are therapeutically intractable. To identify new therapies for this disease, we undertook an isogenic CRISPR-interference screen t
Externí odkaz:
https://doaj.org/article/07f18a49460b42de8d0814e3d0166e10